Table 3.
Positive predictive value per diagnosis
| Diagnosis | TC (%) | UPC (%) | UHC (%) | P‐valuea |
|---|---|---|---|---|
| BCC | 67·9 | 52·2 | 48·4 | 0·008 / < 0·001 / 0·50 |
| SCC | 40·8 | 19·2 | 31·6 | 0·01 / 0·48 / 0·06 |
| Melanoma (in situ) | 75·4 | 65·3 | 66·7 | 0·14 / 0·77 / 0·87 |
| AK | 60·0 | 50·0 | 73·5 | 0·70 / 0·79 / 0·25 |
| BD | 75·0 | 61·5 | 0·0 | 0·47 / – / – |
| (Atypical) naevus/lentigo | 77·8 | 66·7 | 57·9 | 0·43 / 0·008 / 0·01 |
| SK | 76·5 | 71·4 | 82·1 | 0·22 / 0·67 / 0·22 |
aTC vs. UPC / TC vs. UHC / UPC vs. UHC.
AK, actinic keratosis; BCC, basal cell carcinoma; BD, Bowen disease; SCC, squamous cell carcinoma; SK, seborrhoeic keratosis; TC, trained cohort; UHC, untrained historical cohort; UPC, untrained present cohort.
Bold represents significant outcomes